Compare ATKR & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATKR | IMNM |
|---|---|---|
| Founded | 1959 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2016 | 2020 |
| Metric | ATKR | IMNM |
|---|---|---|
| Price | $93.87 | $26.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $75.67 | $32.80 |
| AVG Volume (30 Days) | 685.0K | ★ 976.7K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,850,378,000.00 | $6,941,000.00 |
| Revenue This Year | $6.55 | N/A |
| Revenue Next Year | $3.89 | $1,127.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $53.75 | $8.93 |
| 52 Week High | $94.14 | $30.06 |
| Indicator | ATKR | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 71.71 | 51.41 |
| Support Level | $93.32 | $19.28 |
| Resistance Level | $94.05 | $27.14 |
| Average True Range (ATR) | 0.22 | 1.21 |
| MACD | -0.65 | -0.37 |
| Stochastic Oscillator | 95.54 | 22.89 |
Atkore Inc is a manufacturer of Electrical products for the non-residential construction and renovation markets, as well as residential markets, and Safety & Infrastructure products for the construction and industrial markets. The Electrical segment manufactures products used in the construction of electrical power systems including conduit, cable, and installation accessories. This segment serves contractors in partnership with the electrical wholesale channel. The Safety & Infrastructure segment designs and manufactures solutions including metal framing, mechanical pipe, perimeter security, and cable management. These solutions are marketed to contractors, original equipment manufacturers (OEMs), and end-users. The majority of revenue is generated from the Electrical segment.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.